Pharmaceutical

MASH revival with over $2.5bn for innovator drug partnership deals in 2024

MASH innovator drugs witnessed an over $2.5bn increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD).

Apr 3, 2024 - 00:00
MASH revival with over $2.5bn for innovator drug partnership deals in 2024
MASH innovator drugs witnessed an over $2.5bn increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD).
Read the original article

Tags:

Previous Article

A proactive, data-driven approach to closing care gaps in heart disease

Next Article

Ipsen joins the ADC club with deal worth up to $900m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA’s Janet Woodcock to retire early next year

STAT+: FDA’s Janet Woodcock to retire early next year

Nov 17, 2023

STAT+: Bellerophon Therapeutics trial fails despite innovative digital endpoint

STAT+: Bellerophon Therapeutics trial fails despite inn...

Jun 6, 2023

FDA clears UCB’s Bimzelx for psoriasis treatment

FDA clears UCB’s Bimzelx for psoriasis treatment

Oct 21, 2023